Navigation Links
Ganeden Biotech Obtains Self-Affirmed GRAS Status for Probiotic Ingredient, GanedenBC30 (Bacillus coagulans GBI-30, 6086)
Date:12/4/2007

CLEVELAND, Dec. 4 /PRNewswire/ -- An independent panel of scientists has awarded Ganeden Biotech, Inc. self-affirmed GRAS (Generally Recognized as Safe) status for its patented probiotic, GanedenBC30 (Bacillus coagulans GBI- 30, 6086). After an extensive evaluation of research studies and toxicology data, the panel concluded that GanedenBC30 is safe for use as an ingredient in food products. According to the FDA, self-affirmed GRAS status is awarded to any substance that is generally recognized among qualified experts as having been adequately shown to be safe under the conditions of its intended use.

(Logo: http://www.newscom.com/cgi-bin/prnh/20041213/CLM031LOGO )

"With so many health benefits and potential applications available for GanedenBC30, licensing partners now have one more level of confidence in the safety of GanedenBC30 as an ingredient," commented Ganeden's Founder and Chief Scientist, Sean Farmer. "Achieving GRAS status further supports our commitment to provide superior probiotic bacteria in widely available premium products," Farmer said.

GanedenBC30 (Bacillus coagulans GBI-30, 6086) is a high-survivability strain of the probiotic, Bacillus coagulans. In addition to food products, GanedenBC30 is currently used in a broad range of applications including dietary supplements, animal health products, feminine hygiene and topical applications. The probiotic cells in GanedenBC30 are able to survive very harsh manufacturing processes, do not require refrigeration and survive gastric acidity. Overall, GanedenBC30 has shown to be heartier than other probiotic strains and exhibits excellent stability, offering more flexibility in manufacturing and delivery systems.

"GanedenBC30 is different from other traditional bacteria because it is surrounded by a natural organic layer that serves as a protective shield against the manufacturing process, shelf life and stomach acids and intestinal bile," explains Farmer. "Because of this unique make-up, GanedenBC30 survives the hostile environment of the stomach, colonizes the intestines, and produces lactic acid, which are all critical factors to the success of a probiotic. That's why we initially chose a strain of Bacillus coagulans over other conventional probiotic strains," explained Farmer.

About Ganeden Labs

Established in 2006, Ganeden Labs is the licensing and development division of Ganeden Biotech, making proprietary, patented probiotic technology available for use in innovative products in a wide range of industries. Ganeden maintains an extensive intellectual property portfolio with patent and trademark protection for an array of technologies all over the world. GanedenBC30 and its related patents are available for license in a wide variety of applications. For more information, visit http://www.ganedenlabs.com.

About Ganeden Biotech

Founded in 1997, Ganeden Biotech Inc. is a consumer healthcare company based in Cleveland, Ohio that features a popular line of over-the-counter, products under the brand names Sustenex, Digestive Advantage, and Clearly Confident. Ganeden's oral products including Sustenex and Digestive Advantage contain GanedenBC30, a patented strain of Bacillus coagulans.


'/>"/>
SOURCE Ganeden Biotech
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
Breaking Biology News(10 mins):